Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
8.36
Nov 13 • 3:59 PM ET Dollar change-0.08 Percentage change(-0.95%)
Aftermarket Close
8.36
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
240.96M
Enterprise Value
78.00M
Income
-87.24M
Sales
21.42M
Book/sh
5.93
Cash/sh
6.41
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
111
IPO
May 22, 2013
P/E
-
Forward P/E
-
PEG
-
P/S
11.25
P/B
1.41
P/C
1.30
P/FCF
-
EV/EBITDA
-
EV/Sales
3.64
Quick Ratio
6.68
Current Ratio
6.68
Debt/Eq
0.13
LT Debt/Eq
0.11
Option/Short
Yes / Yes
EPS (ttm)
-3.08
EPS next Y
-3.50
EPS next Q
-0.82
EPS this Y
-22.22%
EPS next Y
-19.41%
EPS next 5Y
-11.79%
EPS past 3/5Y
- 7.53%
Sales past 3/5Y
-31.15% 47.77%
EPS Y/Y TTM
-25.04%
Sales Y/Y TTM
-74.84%
EPS Q/Q
47.29%
Sales Q/Q
19.07%
Insider Own
8.36%
Insider Trans
0.00%
Inst Own
76.84%
Inst Trans
-4.92%
ROA
-35.06%
ROE
-44.37%
ROIC
-46.66%
Gross Margin
88.14%
Oper. Margin
-463.82%
Profit Margin
-407.24%
SMA20
-18.05%
SMA50
-32.74%
SMA200
-8.17%
Trades
Shs Outstand
28.46M
Shs Float
26.41M
52W High
17.96 -53.45%
52W Low
5.50 52.00%
Volatility
8.59% 10.04%
ATR (14)
1.07
RSI (14)
36.96
Beta
2.62
Rel Volume
0.38
Avg Volume
990.68K
Volume
377,086
Perf Week
-19.23%
Perf Month
-25.82%
Perf Quarter
2.70%
Perf Half Y
11.91%
Perf YTD
36.38%
Perf Year
7.59%
Perf 3Y
-52.80%
Perf 5Y
-77.75%
Perf 10Y
-38.44%
Prev Close
8.44
Price
8.36
Change %
-0.95%
Consensus
Strong Buy
Avg. Price Target
$23.80
Implied Upside
+184.7%
Analysts15incl. previous ratings
Rating Distribution10 Buy · 3 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 24, 2026Upgrade
C logoCCitigroup
Neutral → Buy$20+139.2%
Mar 18, 2026Initiated
RILY logoRB. Riley Securities
Buy$22+163.2%
Jan 23, 2026Initiated
RRoth Capital
Buy$20+139.2%
Oct 24, 2025Downgrade
HH.C. Wainwright
Buy → Neutral$12+43.5%
Oct 23, 2025Downgrade
C logoCCitigroup
Buy → Neutral$12+43.5%
Oct 22, 2025Downgrade
GGuggenheim
Buy → Neutral
Sep 04, 2025Resumed
HH.C. Wainwright
Buy$60+617.7%
May 28, 2025Initiated
BNS logoBScotiabank
Sector Outperform$32+282.8%
Jan 28, 2025Initiated
BBTIG Research
Buy$41+390.4%
Aug 12, 2024Initiated
LLeerink Partners
Outperform$70+737.3%
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
FounderMr. Joseph E. Payne M.Sc.
FounderDr. Padmanabh Chivukula Ph.D.
Principal Accounting Officer & ControllerMr. Joseph Roberts
Chief Legal OfficerMr. Lance Kurata
Chief Financial OfficerMr. Dennis M. Mulroy